Short answer
BIOLIFE SOLUTIONS INC (BLFS) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 8.01 (Other Events). HSR antitrust waiting period expired September 3, clearing a key regulatory condition for Repligen’s acquisition of BioLife.
BIOLIFE SOLUTIONS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- HSR antitrust waiting period expired September 3, clearing a key regulatory condition for Repligen’s acquisition of BioLife
- Consideration remains $11.25 cash plus 0.1442 Repligen shares per BioLife share
- BioLife stockholder approval remains required at the October 5, 2026 special meeting
- Closing still depends on customary conditions, creating execution and timing risk for shareholders
- Repligen shareholders face potential dilution from shares issued in the transaction
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOLIFE SOLUTIONS INC 8-K filings
Get the next BLFS 8-K as it lands
Follow BLFS for push alerts, or ask the research agent what this filing means.